June 20, 2017 / 10:16 PM / a month ago

BRIEF-Novo Nordisk receives positive vote from FDA advisory committee

1 Min Read

June 20 (Reuters) - Novo Nordisk

* Receives positive 17-2 vote from fda advisory committee that victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

* Look forward to working with FDA to include important results from leader trial in Victoza(®) label

* Supplemental new drug application for Victoza's regulatory feedback in US is expected in q3 2017

* Says with the vote today Co is one step closer towards a cardiovascular indication for victoza to reduce risk of cardiovascular events

Source text for Eikon:

Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below